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PREFACE 
In the course of previous work to produce a ‘roadmap for the development of precision medicine’ 
(published in 2017) the International Risk Governance Center (IRGC) at EPFL had identified five specific 
challenges that needed to be addressed: 
1. Trust: engaging citizens and patients in biomedical data collection and sharing schemes 
2. Data security: securing data transactions for privacy and confidentiality (including cybersecurity), 
while at the same time making the data available for research (interoperability) 
3. Incentives: helping scientists and technologists organise so that they work more effectively 
together (competition, rewards and incentives) 
4. Economics: making the case that investing in precision medicine (research and implementation) is 
cost-effective 
5. Regulation: helping regulators design licensing mechanisms to assess efficacy and safety with 
acceptable certainty without constraining innovation 
On 23-24 November 2017, IRGC organised with support from the Swiss State Secretariat for Education, 
Research and Innovation (SERI) and the Swiss Personalized Health Network (SPHN) a multi-disciplinary and 
multi-stakeholder workshop on the theme of Trust in Precision Medicine. The objective was to gain insight 
into practical ways to build trust in and within the field of precision medicine. 
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HIGHLIGHTS by IRGC1 
Precision medicine is individual- and patient-centric. However, trust in precision medicine is far from being 
limited to trust from individuals and patients. Each actor or process in the system should be trustworthy for 
what it aims to deliver. Although it is difficult to define indicators and criteria of trust or trustworthiness for 
each, this is a necessary exercise for the successful development of precision medicine. It is equally difficult 
to assess whether each actor or process is trusted in a given context or country, because of the complex 
network of institutions collaborating with each other in a multi-faceted process. Collaboration between 
actors, communication and transparency is thus an important cross-cutting theme, with the aim to reframe 
and redesign the trust system to accommodate precision medicine’s goals to improve the practice of 
medicine in general.  
The concept of trust is central to each of the three stages or components of the precision medicine process 
(value chain): the collection of data, the analysis of data and the provision of health and medical care. 
Data collection 
The process begins with individuals who participate in data collection schemes, as either or both ‘donors’ 
who wish to contribute to research, and patients with certain medical needs. They ‘donate’ tissue or DNA 
that contains data that is private and confidential to them. They also give (or should give) access to medical 
health records and other lifestyle information, which is often collected without their full awareness. Here, 
individuals demand trustworthiness on the part of those who collect the data and other information that 
the process will be secure and protect their privacy, and that the information will not be used against them 
in any way and at any point in time. In addition, individuals and patients want to trust the whole precision 
medicine system. In this system, sharing tissue and data should be made for the public good, and some 
benefit must returning to citizens and patients. Trust can thus be seen as the overall sentiment that, all 
together, the actors that collect, give access to and use the data, do it in a fair and responsible manner. 
Data analysis and governance  
The system of data analysis and governance must be transparent, reliable and accountable. The data must 
not be stored and processed in a way that could cause prejudice to individuals. Here one must consider 
that, beyond ensuring data security and oversight or governance, it is increasingly the governance of 
algorithms that will matter. The prospect of using artificial intelligence must not give the impression of 
creating a black box. However, aiming for transparency of algorithms and accountability of their managers 
will become increasingly complex. It will thus be important that each actor finds trustworthiness in other 
actors with which they collaborate. Overall, governance of data analysis is needed to establish and maintain 
trust in the data system. 
Provision of medical care 
At the end of the process, precision medicine must improve public as well as individual health. Patients 
expect that their medical needs will be met. Here, each patient wants trustworthiness on the part of those 
who provide diagnostics, prevention or therapy. This concerns the medical practitioners or ‘counsellors’, 
hospitals, the pharmaceutical industry, regulators and payers particularly. All these actors must determine 
for what they want to be trustworthy, and be able to demonstrate their trustworthiness. At the same time, 
individuals must trust the whole precision medicine system, or perhaps the entire health and medical 
system, for its capacity to improve health. Criteria of accessibility and affordability of new ‘genomic-
enhanced’ medicine are key to contributing to overall trust in the system, which means that fairness and 
equity are perceived as important for the success of precision medicine. 
 
                                                          
1 These highlights reflect the views of IRGC, as main organisers of the workshop 
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This summary of the workshop discussions2 on the ‘governance of trust in precision medicine’ presents 
some of the important points and insights elaborated by the participants.   
The workshop also highlighted the importance of additional work about: 
 Issues of data governance: data security and protection of sensitive data, privacy, algorithmic 
decision-making, and platforms for data sharing 
 Cost-effectiveness, economics and payment schemes: making precision medicine affordable in the 
practice 
 The need to improve collaboration: all workshop participants, representing different stakeholders, 
demonstrated their willingness to collaborate with each other to address and resolve any 
outstanding issue. 
  
                                                          
2 The programme of the workshop was organised to discuss several predetermined questions. See the questions 
discussed during the workshop in Appendix 2. 
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WORKSHOP SUMMARY 
This summary of the workshop discussions presents some important aspects raised by the participants. 
Participants in the workshop are listed in Appendix 3. 
1. Setting the scene 
Broadly speaking, precision medicines are of two distinct types.  The first type – a more personalised 
precision medicine – entails gene therapies or regenerative medicines whereby therapeutics are tailored to 
the individual.3 In this case, trust often results from patients’ needs being met, especially in situations when 
patients have no other treatment options and remain more worried about their immediate survival. Since 
enabling more advanced therapeutics implicates both licensing and payment arrangements, trust over 
regulators’ and payers’ decisions and about patients’ access to such therapeutics emerge as key points of 
consideration. Licensing is particularly complex when traditional clinical trials are not well suited to small 
sample sizes that may characterise this type of precision medicine.4 This type of more personalized 
precision medicine nevertheless requires gaining broader societal trust and involvement, particularly on 
matters of accessibility and equity.  
The second type of precision medicine – more probabilistic, sometimes preventative in character – entails 
the more targeted use of traditional small molecules thanks to information on genomics, health records 
and other types of data that can facilitate better drug safety and effectiveness. This targeted approach is 
about working more intensely with flows of shared data and thus requires access to quality data, but also 
an investment in the data analytics for the development of appropriate diagnostics. Issues of trust, in this 
case, revolve largely around the appropriate sharing and use of data, namely trust around access to data, 
the integrity of data, as well as around data processing and analytics that can help make the practice of 
medicine better targeted where possible.  
Boxes 2-5 illustrate the development of precision medicine in different countries and contexts, some more 
successful than others. While slightly different trust issues may arise for different types and applications of 
precision medicine, or for different publics and stakeholders, it remains important to also gauge the trust in 
the global system of precision medicine.  
2. On trust and trustworthiness 
Workshop participants’ discussion on trust concerning precision medicine was informed by a background 
paper5 (see Appendix 1) that was subsequently published in Omics6 (Adjekum, 2017). Key, in this respect, 
were the distinct concepts of trust and trustworthiness, which are often used interchangeably. Whereas 
trust is understood as an expectation of positive motives (Rousseau et al., 1998), trustworthiness is 
perceived as a characteristic that is projected onto an individual or group (Holm and Nystedt, 2010). One 
can further argue that for trust to be established, trustworthiness needs to be demonstrated; or that if 
trust is a response to trustworthiness, we should aim to put “trustworthiness before trust” (O'Neill, 2002). 
The background paper thus suggested a working definition of trust of individuals in precision medicine as 
“the willingness of a trustor to accept the potential risks involved in the sharing and further use of their 
personal data resulting from both optimism about the trustees' goodwill and interest in the public good.” 
Participants sought to cast the discussion on trust and precision medicine along more pragmatic and 
relatable concerns as well. They suggested, for example, three types of questions that individuals should be 
                                                          
3 As exemplified by CAR T-cell therapy—a rapidly emerging form of cancer treatment 
4 The European Medicine Agency (EMA) is pioneering with adaptive licencing pilots that address this problem. This is a good 
example of the adaptation of regulation to the new requirements that are faced by smaller indications of evidence on 
effectiveness. US FDA is also moving in that direction. 
5 Available here: https://irgc.epfl.ch/page-148683-en.html  
6 Afua Adjekum, Marcello Ienca, and Effy Vayena. What Is Trust? Ethics and Risk Governance in Precision Medicine and Predictive 
Analytics. OMICS: A Journal of Integrative Biology. December 2017, 21(12): 704-710. https://doi.org/10.1089/omi.2017.0156 
Trust in Precision Medicine – IRGC 23-24 November 2017 workshop summary 
6 
able to ask actors in the precision medicine system: 
1. Why are you pursuing precision medicine? ‘Can you explain to me what you are doing?’  
2. Who benefits from precision medicine? ‘Me and who else?’  
3. What confidence can we reasonably have in precision medicine? ‘How sure are you that what you are 
telling me is right?’ 
This line of questioning that can resonate with varied parties brought into the conversation the more 
pragmatic concerns about enabling quality precision medicine with the more slippery notions of trust and 
trustworthiness that matter for the acceptance of it.  
Drawing from the themes and insights elaborated by participants in different working sessions, this 
summary report synthesizes how trust percolates into the three key components of the precision medicine 
process namely the collection of data, the analysis of data and the provision of health and medical care, 
and cross-cutting issues and reflections around communication as well as mandating and assessing trust. 
3. Trust around data collection, use and analysis of data, and provision of health and 
medical care   
It is useful to begin by noting that the process of delivering precision medicine includes the collection of 
data, the analysis of data, and the provision of health and medical care.  Synthesizing along these distinct 
components allows us to see how different actors and stakeholders partaking in the discourse around trust 
in precision medicine are grappling with different ends, or aspects of the matter, but often with shared or 
interchangeable insights.  
3.1 Trust at the level of data collection  
Developing more accessible, integrated data sets including genomics health records and other data is 
essential to precision medicine. The process begins with individuals who participate in data collection 
schemes, as donors’ who wish to contribute to research, and/or patients with distinct medical needs. They 
‘donate’ tissue or DNA that contains data that is private and confidential to them. Moreover, precision 
medicine requires not only access to medical health records and other lifestyle information –at times 
collected without their full awareness of it – but it also requires access to high-quality data, and thus ways 
to curate the data. At the level of data collection, the question of trust thus becomes entangled with 
concerns about privacy, consent, security of data transactions as well as assuring the quality of data. The 
dilemmas that were discussed include: 
 How to reconcile privacy and sharing, or what should be in the private versus public domain? 
 How to implement broad consent (‘opt-in’) and handle incidences of ‘opt-outs’?  
 How to secure sensitive data while also recognizing the potential of the technology itself to 
contribute to certain broad distrust (as illustrated by the massive attacks on health data)?  
 How to navigate the trade-off between giving patients better control over their personal health 
information on one end and supporting medical research whose value accrues as data is shared, 
curated and aggregated on the other end?  
Beyond articulating and debating these dilemmas, workshop participants further contributed the following 
insights that help advance the conversation on trust and data collection for precision medicine: 
 Allowing opt-ins and opt-outs may help express consent in the more mechanical or narrow 
regulatory sense, but opt-outs and opt-ins in precision medicine programmes are not necessarily 
adequate indicators of people’s trust or mistrust of them. They require a more nuanced 
interpretation. Individuals who opt-out of a programme may display disagreement with it but not 
necessarily a lack of trust in it. At the same time, people who opt-in may not trust the whole 
programme. What further complicates the matter are potential gaps between regulation and 
human behaviour. For example, regulation may seek to maximize protection of private and 
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confidential data, but individuals behave differently in practice. In the UK experience with 
care.data, only one in 45 individuals opted out after it was revealed to the public that the 
programme had no plan for Intellectual Property (IP). So far, opt-out rates of precision medicine 
programmes are low.  
 Participants further noted that many patients would like to see more sharing of data as a way of 
enabling faster access to treatments and are more willing to give consent for broad purposes, like 
improving the practice of medical and healthcare provision. Consent, in this view, involves more 
and better engagement of individuals on how their data could be used for the benefit of society as 
a whole and how that can trickle back to them.  
 While important to cast consent on broader terms and purposes, protecting against adverse data 
use remains important for mobilizing it. Patients worry about the secondary use of their material 
and care to know if there is a risk that they would be hurt when they give access to their data. Thus 
governance of data use, reuse and misuse takes greater salience in the debate. The attending 
question that arises is whether individuals can have greater control, even property rights, over their 
data.   
 There are no intellectual property rights on tissue or body parts in general. While possible to 
argue that giving access rights to individuals and sharing profits with them is a way to include them 
into developing precision medicine, it remains important to decouple the basis of consent from the 
question of ownership. Even if data ownership was possible and legal, what seems overlooked or 
misunderstood is that data does not accrue value at the point or moment of collection, but as it is 
aggregated, curated, and analysed. Property rights are thus established later in the process and on 
the basis of investments made to develop this knowledge. Educating the public about misguided 
expectations around ownership rights in precision medicine can help adjust expectations and gain 
broader societal trust.  
 More generally, the promise of data control seems misleading as there is an important balancing 
act between optimizing for medicine and optimizing for individual rights, like privacy and 
ownership. Sharing tissue and data is intended for the public good, with some benefits that come 
back to patients as well as the stakeholders that develop the practice. If, on the other hand, 
researchers and industry do not have the information, they cannot develop precision medicine 
treatments or solutions. This trade-off manifests itself along various points in precision medicine, 
but at the level of data collection, the requirements for data protection and anonymization must be 
balanced with the need for data curation. Precision medicine depends on high-quality data, and 
this requires data identification or being able to check, confirm, re-test and deal with anomalies. 
Given that most of the methods used to protect individuals and their medical data have some 
degrees of anonymization and de-identification, data curation remains difficult.  
 While there is some broad mistrust of technology (as illustrated by the massive attacks on health 
data), technology can also help build trust in data collection for precision medicine. It can do so 
by way of a number of privacy enhancing techniques, like various sorts of cryptography7; statistical 
techniques whose objective is to avoid that the response to a query leaks too much sensitive 
information and leads to the origin or source of the data; use of blockchain technologies to 
decentralize storage and distribution of sensitive data with a view to keeping them as close as 
possible to those who value data protection and privacy; etc. Practitioners further noted that often 
in a hospital or research settings, the norm is that patients’ data cannot be accessed without 
approval by ethics committees, and cannot be used without respecting certain rules and 
regulations. However, some facilities may have inadequate health data management practices, 
including a poor understanding of data and IT security. 
                                                          
7 There are various sorts of cryptography, including symmetric cryptography, asymmetric cryptography, privacy-preserving 
encryption, and in particular homomorphic encryption. www.genomeprivacy.org is a website that presents various advanced 
techniques to protect data in personalised health. 
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 Beyond more technical solutions, it remains important to recognize a certain trade-off between 
the ideal ethical framework and the actual objective that precision medicine can help achieve. 
There is no such thing as ‘sufficient’ level of trust in how data is protected, not least because the 
importance of data protection remains fairly context dependent. Expectations of data protection 
are less important, for example, when there is a pressing or critical medical need. Individuals may 
be more willing to share if they perceive how this improves the health circumstances around them. 
To navigate this gap between ideal frameworks and contextual circumstances in ways that inspire 
and mobilize trust, participants explored other modes of engaging patients as partners, even co-
producers of data, or science.  
 Patients’ organisations of various sorts (patient support, cooperatives for data sharing, advocacy 
groups, etc.) are important elements in the trust chain. It would be useful, for example, to build 
platforms for patients’ data uploading, peer-to-peer information and patient engagement. In the 
social media space, new organisations or portals like ‘Patients like me’ reconfigure the traditional 
way of ensuring trust. This type of portals helps create self-trust mechanisms or ‘do-it-yourself’ 
self-help systems that fill data gaps for the purpose of evaluating what works and what does not 
work for patients ‘like me’. This approach to addressing problems of trust is worth exploring for it 
empowers patients in ways that render the fear of losing control over their data less salient. 
3.2 Trust around data use and processing 
Important trust considerations arise at the level of data processing and analytics, including questions about 
data use, re-use and misuse in a changing paradigm where medical research involves not only more intense 
data flows but also new ‘data players’ (the so-called ‘IT giants’ like Google, Amazon, IBM and others). This 
expansion of the precision medicine makes for a novel landscape or eco-system with a larger set of actors, 
intensified data flows and multiplied data points or sources. It brings more fundamental changes to how 
data is perceived and processed and blurs more traditional boundaries and roles. Such change thus raises 
novel questions about: 
 envisioning trust in institutions but also networks of collaborators (e.g. how different institutions 
can become more trustworthy, what different actors want to be trusted for but also how to trust 
networks of collaborators in a changing landscape of players) 
 facilitating the right dynamics of accountability and degrees of transparency (especially vis-à-vis the 
use of algorithms and artificial intelligence in medical research and decision-making as well as vis-à-
vis data-pooling and data-integration schemes emerging within the industry and across medical 
researchers)  
 attributing legal responsibility and liability where necessary (i.e. establishing rules that define roles 
and relations between parties and provide confidence that individuals’ interests will be addressed 
in case of adverse use).   
Data security is of prime importance, and the protection of sensitive data through secure IT and practices is 
a critical trust factor. Hospitals are frequently subject to cyber-attacks, and as important nodes in the data 
analysis process they must work to reassure patients and medical professionals. In addition, data use and 
analysis must be transparent, accountable and reliable enough so that both ‘donors’ of data and ‘users’ of 
health care trust the data governance system, including that it may not cause prejudice to them. While 
difficult to identify a single institution in which trust could be deposited, when it comes to governance of 
data use and analytics, particular attention goes to the challenges of enabling intra-professional and intra-
industry collaborative schemes, as well as the role of algorithms and Artificial Intelligence which can give 
the appearance of a black box. The following insights from workshop participants can help advance the 
conversation on trust and the governance of data use and analytics in precision medicine:  
 Collaboration between actors is of utmost importance in the context of trust in precision 
medicine. There is a common interest in collaboration for developing more accessible, integrated 
Trust in Precision Medicine – IRGC 23-24 November 2017 workshop summary 
9 
data sets including genome, health records and other data to serve the needs of diverse 
populations and stakeholders. Industry consortia are one solution, but a broader approach to 
creating large integrated data sets (that might be divided into de-identified aggregates, with easy 
opt-out form consent) can help broaden trust. Such multi-stakeholder consortia would be best 
coordinated by respected, trusted and neutral actors. 
 Collaboration must also contend with competitive dynamics, legal challenges and inter-
professional tensions around sharing, pooling, or integrating data. Coordinating the sharing of 
extensive data pools in the pharmaceutical industry is, for example, a complicated legal discussion 
of data ownership. Thus trust also requires players in data analytics to demonstrate that they can 
find ways to share data in a legal manner and engage in ‘competitive collaboration’. In a similar 
vein, inter-professional trust among health care professionals is not to be underestimated in that 
they might not always want other care professionals to look at their data and practices. One 
solution would be partnerships between industry, care practitioners and governments, where 
policy-makers help create the platform for the collaboration and sharing of data. 
 Legal aspects may become increasingly important in that laws and regulation can contribute to 
establishing the basis for trustworthy relationships in a context of blurred roles and 
responsibilities. The principle of fiduciary duty, for example, applies to the classical physician-
patient relationship, but the precision medicine ecosystem involves so many other actors who use 
the data, that it may no longer be relevant. There is a new discussion about the stewardship model 
that extends how researchers ought to think and how those who control the databases should 
behave. The objective is to stretch the responsibility existing in the patient-doctor relationship to a 
larger set of actors involved in data processing and in so doing, create the conditions for trust in the 
governance of data use and re-use.  
 Collaboration is needed in particular to address the so-called ‘Big Data challenge’ which implies 
that, even if individuals trust the local system that will encrypt, analyse and store their data, their 
data may eventually end up in the hands of other actors, or industries. New actors like ‘IT giants’ 
(IBM, Google, Amazon and others) are entering this domain, with extensive datasets and methods 
that differ from those traditionally employed (e.g. in the pharmaceutical industry). For example, 
Google and Microsoft are pursuing genomic research, and Amazon may soon deliver medication. 
Their behaviour and effective success in delivering useful data and services will affect trust in 
precision medicine. At the same time, among traditional companies, outsourcing is becoming the 
norm, including in the data area and including to those ‘IT giants’ mentioned above. As private 
companies partner with a large number of providers, including academia and start-up companies, 
and outsource innovation, how to ensure the trust in that enhanced ecosystem? Thus varied 
players need to find ways to make their trustworthiness visible, such as by way of collaboration, 
even engagement with contrarian views. It will further be important that each actor finds 
trustworthiness in other actors with whom they collaborate.
 Trust increasingly becomes a matter of trusting networks of actors of various types. Individual 
institutions, be they pharmaceutical or technology companies, hospitals or academic institutions, 
are not necessarily fully in control of everything, but they are still liable for what happens in their 
ecosystem when they engage or outsource to other actors that undertake activity on their behalf. 
There is thus a growing need to move away from strict compliance programs that solely focus on 
internal processes and look into the broader ecosystem. Trust can no longer be built and sustained 
individually.  
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Box 1: OECD recommendations on health data governance  
OECD recommendation on health data governance adopted in 2016 includes twelve principles for 
building a governance framework that could reconcile risks and benefits and create the conditions 
for trust.  
Particularly relevant to the trust issue are: 
 Engagement and participation 
 Clear provision of information 
 Effective consent and choice mechanisms 
 Controls and safeguards 
 Approval procedures for the use of personal data 
 Recognition of the role of technology 
 Public disclosure and transparency 
 Certification or accreditation.  
Implementation of these measures could provide a proxy for trustworthiness. 
http://www.oecd.org/els/health-systems/health-data-governance.htm  
 Transparency of algorithms and accountability of Artificial Intelligence (AI) decision-making will 
become increasingly complex and relevant. Algorithms are the lifeblood of precision medicine and 
effective individualised treatments, but they are often not very transparent nor easily understood. 
The use of Artificial Intelligence – using computer science to help understand the mechanisms of 
disease and human health – can give the appearance of creating a black box. Establishing 
algorithms’ transparency is challenging in practical terms but remains important for facilitating 
trust in the underlying technology. Governance principles should be established to enable the 
accountability of AI-based decisions, which may also require some form of regulatory oversight.  
Ultimately, individuals seek trustworthiness on the part of those who collect, share, analyse and/or use the 
data and resulting information, and assurances that those will not be used against them in any way or at 
any point in time. In addition, individuals and patients seek trust in the whole precision medicine eco-
system, which is composed of various actors, with diverse roles, rules and collaborative challenges. Trust 
can thus be seen as the overall sentiment that, all together, the actors that collect, give access to and use 
the data, will do it in a fair and responsible manner. Lastly, individuals and patients also need to trust 
precision medicine’s broader purpose, namely that it will improve the provision of health and medical care. 
The latter raises its own set of trust considerations, particularly vis-à-vis those (actors) implicated in the 
more direct provision of health and medical care, i.e. medical professionals, payers as well as companies. 
3.3 Trust and the provision of health and medical care with precision medicine  
At the far end of the process, precision medicine aims to improve public as well as individual health. There 
is an expectation that patients’ medical needs should be met. Thus individual patients seek trustworthiness 
on the part of those who provide information for diagnostics, prevention or therapy. This concerns the 
medical practitioners or ‘counsellors’, hospitals, the pharmaceutical industry, regulators and payers who 
must probe and determine for what they want to be trustworthy, and find ways to demonstrate it (their 
trustworthiness). At the same time, individuals must trust that the precision medicine system can be 
properly accommodated and integrated within the broader health and medical system so as to witness or 
experience its capacity to improve the delivery of healthcare.  
Workshop participants discussed the centrality of the criteria of accessibility and affordability of new 
‘genomic-enhanced’ medicine for establishing an overall trust in the system, but also the inclusivity and 
representativeness of data in precision medicine, the role of medical professionals in redefining health as 
well as their pragmatic resistance to precision medicine, and ultimately, whether precision medicine could 
Trust in Precision Medicine – IRGC 23-24 November 2017 workshop summary 
11 
be over-promising and/or under-performing (vis-à-vis the more traditional health systems in place). On 
these points, the following insights accrued: 
 How medical practitioners participate will determine to a large extent how patients trust the 
system of precision medicine. Indeed, medical professionals are important actors in the release of 
certain key tensions to precision medicine, such as tensions between patient empowerment and 
paternalism in the medical sector (e.g. medical doctors must prepare to see patients who have 
acquired information about their genome even before consulting them) and tensions between the 
promise of ‘precision’ and the inherent uncertainty in precision medicine. The latter may prove 
particularly troubling to patients and professionals alike, in that they may have more data at their 
disposal, and precision medicine may even enable preventative medicine, but it will not do away 
with scientific uncertainty per se. These tensions may not easily dissolve, but at a minimum, it 
remains important that they do not destroy the confidence that people have in the medical 
professionals. As precision medicine will enable preventive medicine, the medical professionals will 
have an important role in providing guidance to their patients, namely to help redefine what health 
is and how to stay healthy, without transforming every citizen into a future sick person.  
 A significant part of health personnel exhibits pragmatic resistance to precision medicine.  
This resistance may be driven by fear that hard-won clinical skills could be obliterated by 
algorithms. It may at the same time be driven by difficulties in envisioning new roles and working 
with new kinds of knowledge. Preventive, predictive precision medicine, for example, creates 
situations in which the doctor is no longer the central and ultimate medical authority but the 
professional who helps patients making sense of large volumes of medical data. It is still unclear 
whether medical doctors will in the future be responsible for delivering data analytics information 
to patients or whether new professional roles will emerge (e.g. health coaches) and this lack of 
clarity on changing roles. But resistance may also be partly driven by concerns about data integrity 
and representativeness, leaving clinicians unconvinced that precision medicine will help their 
particular patients. The ‘All of Us’ longitudinal study in the US for example (Box 2) points out the 
difficulty of gathering a sample that is representative of the underlying population.8 This, in turn, 
raises questions about just how representative and tailored to patients’ needs precision medicine 
can be.9  
 The degree to which precision medicine builds or exacerbates existing inequalities in access to 
medicine can significantly impact the trust that different patients and practitioners place in it. 
The need for precision medicine to further the common good is a common theme that has yet to 
be reconciled with the fact that it may increase inequalities and health disparity. To this effect, 
perceptions about access to precision medicine, and the affordability of it, can significantly affect 
the trust people place in it. In some contexts, the overall trust issue may be less about data privacy, 
ownership or of consent than about assuring access to and affordability of precision medicine.  
 Providers of medical and healthcare, including payers and industry, must strive to make precision 
medicine affordable and inclusive. Health care systems are often very resource constrained and 
thus pricing and licensing around precision medicine must take this into account. A possible 
approach is to shift to ‘value-based healthcare’ which has a more holistic approach to the pricing 
for drugs and treatments (i.e. considering the total cost of disease over the life of a patient). Drugs 
and treatments thus would be priced in relation to the benefit, or added value, that they deliver to 
society. If the health system, including payers, is not able to reform to make precision medicine 
available and affordable, then precision medicine itself may be criticized for being too expensive, 
                                                          
8 E.g. in the first phase, less than 4% of the data were from Americans that were not of middle or upper class standing and with 
other than European ancestry; the percentage grew to 20% but this is still not representative of the US population in which more 
than 50% of people who have no linkage to European ancestry 
9 80% of Americans are in favour of the programme, but this percentage falls to 50% among Afro-americans, probably because of a 
history of experimentation on under-represented minorities 
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elitist and generally over-promising. On the other hand, if existing health systems are already 
struggling with respect to access and affordability, then a more honest conversation must take 
place about what conditions can progressively develop to achieve cost-effectiveness and inclusion 
through precision medicine10.  
 Taking a long-view to precision medicine might be more constructive than premature conclusion 
on whether it is over-promising or under-delivering. Disappointments about slow or incomplete 
progress can be squared with the fact that the health system cannot yet fully use the data and 
learnings from all the patients. As medical education progressively adapts and trains young 
physicians in the disciplines involved in precision medicine (genetics but also data integration, 
curation and analysis, algorithms and statistics, etc.), medical practitioner resistance may 
progressively disappear. Small-scale deliverables that will act as a proof-of-concept can be very 
helpful in this respect.  
4. Communication and transparency for precision medicine  
A cross-cutting remark from practitioners, industry representatives, researchers and patients is that 
working to build trust in precision medicine requires large, targeted and sensible communication efforts. 
 First, we need to learn how to better communicate to the public and to professionals. Effective 
communication is a dialogue among various parties who often have different cultures, concerns, 
needs, perceptions and even emotional approach to health and disease. Communication begins 
with the mapping of actors and the identification of who needs to communicate what, to whom, 
how, and for what objective. It must also acknowledge that emotions may drive behaviour, with 
the effect that some individual choices may be seen as irrational trust or distrust, when facing 
specific situations. 
 What to communicate? Those who communicate must determine what is needed to achieve 
precision medicine. For example, it is important to communicate the underlying uncertainty that 
prevails in precision medicine, in order to manage the expectations from precision medicine: do not 
overpromise. Communication about consent-related issues (what research participants agree to 
share and how) should convey information in a way that can be understood, and that can foster 
meaningful exchange between different type of audiences, for an informed decision. Particularly 
challenging in communicating about precision medicine is the possibility that people may 
increasingly look for information that is available on social media or the Internet, some of which 
may not be the most trustworthy. While experts may struggle to deliver a unified perspective on 
precision medicine that is easily relatable or understandable for a broader audience, it may be 
relevant to communicate about risks and benefits, whether they are scientifically assessed or 
emotionally perceived. There may be over attention to data-related issues, in contrast to attention 
to risks and benefits, which may be easier to understand by individuals who have to make up their 
own mind and decisions. 
 We also need to exercise some caution with respect to communication. Branding exercises that 
were or are undertaken by certain governments to promote the common good in order to mobilise 
donors can be analysed as initiatives to ‘manufacture’ trust. Hard campaigning and voluntarist 
campaigns may not be an effective way of engaging participants. Precision medicine needs a quite 
strong presence in the public debate, yet at the same time, it must not be promoted too 
aggressively on ‘promises’ or with misleading expectations.  
 Transparency is an important factor of trust and can provide evidence of trustworthiness, but it 
has to be carefully calibrated. The relationship between transparency and trust is complex in that 
too much transparency (e.g. revealing sensitive information) can brew distrust as can a lack of 
transparency (e.g. AI as the ‘black box’, or lack of transparency on who decides what treatments 
                                                          
10 IRGC’s forthcoming workshop with experts will discuss ‘The Economics of Precision Medicine’, in particular questions of 
appropriate pricing and changes in payer and economic models.   
Trust in Precision Medicine – IRGC 23-24 November 2017 workshop summary 
13 
are funded). The existence of a social and political public dialogue is essential in this respect. Trust 
depends on the process by which information is communicated to and discussed with the 
stakeholders. This process must have some form of legitimacy. In addition, information and 
openness to it are needed to substantiate the dialogue.  
 Transparency should be discussed not only at the level of data protection, sharing and curation, 
but also at the level of funding/payment and relations with payers, industry and regulators. The 
role of the industry in manufacturing drugs has to be transparently explained to stakeholders along 
with the involvement of technology companies and the use of algorithms and AI in processing data. 
For example, specific patients whose data is needed to address certain medical needs must be 
sufficiently informed to consent to how their data would be used by public and private research for 
the benefit of society as a whole and in a context that may be commercially beneficial. Or, lack of 
transparency as to who decides what treatments are funded or how drugs are licensed can breed 
mistrust as whether the provision of health and medical care is improving through precision 
medicine.    
5. Mandating and assessing trust  
Participants also reflected on the broader issue of whether trust can be measured and mandated. They 
emphasized that it is essential for any actor to determine for what it should be trusted and what the 
enabling conditions of trust are. The more reflective insights that emerged from the discussions are that:  
 Trust cannot be mandated, in the sense that trust is based on one’s belief (e.g. belief that someone 
will act in the way one expects) and this belief cannot be mandated. But what can be mandated 
are behaviours as expressions of trust, and sometimes, trustworthiness itself. More importantly, 
trust must percolate into the whole environment.  If rules require actors to be trustworthy, it 
makes it more credible that they will be trustworthy.  
 Knowing what we are trusted for is an important determinant of trust, but a frequent mistake 
arises when we confuse whether we trust with whether we like. For example, ‘nice’ people may 
be untrustworthy or distrusted, and trusted people might not be ‘nice’. Thus a more relevant 
question to pose is: what are different entities trusted for? How able are they to deliver? 
Organizations or actors may not always know what they are trusted for and it remains important to 
align their intentions with expectations that people have of them. The goals that we set for 
ourselves are not necessarily the goals others trust us to pursue. It remains useful in this respect to 
distinguish between trust and trustworthiness, and to determine in each case what are people, 
institutions and other actors trusted for. 
 It is understandable that we should want to measure trust, but some limitations arise. For 
example, people may not answer truthfully if they do not trust the researcher. Other limitations 
relate to exactly why we want to measure trust, and it is useful to know how much trust there is in 
different types of partners: institutions, persons, private and public institutions, national and 
international ones. Measurements of trust may often need some form of comparison to alternative 
options.  
 While not always easy to measure, trust can be thought of as a resource – something that we need 
for many of the things we do together – and perhaps not a terribly renewable one if eroded or 
destroyed. It is prudent not to let it decrease too much, because it is easier to protect it early 
rather than build it up again from a situation that has turned sour. Moreover, trust is not static but 
relational and dynamic. It can increase or decrease gradually, appear or disappear suddenly. 
Identifying and measuring the components of trust and its enabling conditions – trustworthiness is 
one of them – helps our understanding of how the dynamics of trust may be changing.  
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More generally, trust can be based on various elements, including: 
 Familiarity and/or proximity: for example between patients and physicians 
 Reliability: this can be provided by technical means, and use of appropriate technology to address 
digital security and privacy issues 
 Accountability: this can be established by experience and reputation.  
 Responsibility: legal systems can establish rules that define conditions of relations between parties, 
and provide confidence that individual’s interest will be protected if something goes wrong. 
Concluding remarks  
People, patients and institutions need to be involved not only in placing trust in precision medicine but also 
in deciding when or where to refuse it. We need, in addition, a set of strategies that earn and provide 
evidence of trustworthiness to evolve and sustain public trust around precision medicine. There is no 
magic recipe, but key ingredients include:  
 Governance and institutions that allow us to judge where to place our trust in precision medicine 
and where to refuse it 
 Transparency, inclusivity, and attention to related concerns such as health disparities and health-
related literacy 
 Respect for different individual preferences, including around consent 
 Meaningful participant engagement and empowerment, with particular attention to topics of 
affordability and access 
 Assuring data integrity, from start to finish, remains essential to facilitating reproducibility, 
replication and representativeness. 
 Responsible data sharing, collection and access, with particular attention to use, reuse and misuse.  
All these elements are needed to create trust in the complex ecosystem that we see evolving around 
precision medicine. The opportunities, as well as the challenges for collaboration, are high-level ones. 
It is worth noting in conclusion that the trust issue in the context of precision medicine is not just about a 
unidimensional relationship or transfer of trust from patients and individuals to the complex medical 
system. It is about asking if and how the trust system can be reframed and redesigned to accommodate 
precision medicine’s goals to improve the practice of medicine in general.  
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Box 2: US PMI / All of Us and trends that characterise the development of precision medicine in the 
US 
The US PMI initiative (now “All of Us”) https://allofus.nih.gov/ will be the largest longitudinal study launched 
in the US. Inclusivity, participant-centric and transparency are three fundamental principles, and all relate to 
trust. One the biggest weakness of the sample collected so far (5000 participants) is that, in the first phase, 
less than 4% of the data were from Americans that were not middle or upper class and with other than 
European ancestry. This percentage has now gone up to 20%, but the sample is still not representative of 
the US population, which is now composed with more than 50% of people who have no linkage to European 
ancestry. Experience so far indicates that, with regards to trust: 
 80% of Americans are in favour of the programme, but this percentage falls to 50% among Afro-
Americans, probably because of a history of experimentation on under-represented minorities 
 The programme seems to exacerbate views about health disparities, and perception of access to 
precision medicine is correlated with income and literacy. The trust issue is less about privacy issues 
than about having access, and affordability. 
 Trust and trustworthiness will be major efforts in the new TOPmed programme (TransOmics for 
Precision medicine)11, as well as in the FAIR principles (Findable Accessible Interoperable and 
Reusable Principles) 
Five trends characterise the development of precision medicine in the US: 
 The shift to a more patient-centric healthcare has implications on trust and trustworthiness, 
particularly when linked with growth in health care consumerism (self-diagnostic on the Internet) 
 Trust and trustworthiness are becoming much more distributed, fragmented among the 
government, doctors and health care systems, experts or the (social) media. 
 Speed, scope and complexity of technological change affect trust and trustworthiness, both 
positively and negatively. For example, AI, machine learning and perhaps blockchain technologies 
are part of the trust-factor. 
 Trust is not just about patients. There are multiple layers and levels of trust involving clinicians, 
researchers and the whole chain of actors. 
 With new actors like Google and Amazon, there is a blurring of traditional boundaries and roles. For 
example, every clinical actor is a data point, every individual is an information node, and every 
individual can also become a research actor. 
 
Box 3: Scandinavia and Finland’s FinGenn project 
In Scandinavian countries, there seems to be a high level of trust between the health systems and citizens, 
which is consistent with a high level of trust in government, deeply rooted in all Scandinavian traditions. For 
example, people in Finland generally say that they are not concerned by risks of misuse of their data: the 
data will not be used against them. The FinGenn project, launched in December 2017, is a public-private 
collaborative genomic research project that will combine genome information with digital healthcare data, 
tapping into 500,000 unique blood samples collected by Finnish biobanks. “Finnish people have strong trust 
in the country’s research and healthcare system, and we are constantly receiving new inquiries from people 
who would like to participate in the project. Transparency is crucial to maintaining the trust of the citizens in 
the research.” https://www.finngen.fi/en/node/38  
 
 
                                                          
11 https://www.nhlbi.nih.gov/research/resources/nhlbi-precision-medicine-initiative/topmed   
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Box 4: Switzerland  
Ethical and trust issues are central to how personalized medicine develops in Switzerland, at various levels. 
Illustrations: 
 Federal legislation 
Message concernant la loi fédérale sur l’analyse génétique humaine  and project of Loi fédérale sur 
l’analyse génétique humaine, July 2017 https://www.bag.admin.ch/bag/fr/home/themen/mensch-
gesundheit/biomedizin-forschung/genetische-untersuchungen/aktuelle-
rechtsetzungsprojekte1.html  
 
 Ethical aspects 
Swissethics ‘manual for research with human subjects’, 2015. The manual intended to convey the 
basic ethical attitude which is required if researchers are to be perceived as trustworthy by 
potential research participants, regulatory authorities, policymakers and the public 
www.swissethics.ch/doc/swissethics/manual_research_nov2015_e.pdf   
Swiss Personalized Health Network (SPHM), Ethical, Legal and Social Implications advisory group 
(ELSIag) addresses ethical, legal and social issues that SPHN will face. It shall: 
- anticipate well-known challenges such as that of appropriated informed consent and privacy; 
- develop mechanisms and processes to handle unanticipated issues and require a swift solution; 
- advise the National Steering Board (NSB) in the development of guidelines for data sharing and 
managing questions of intellectual property, authorship and attribution according to national and 
international standards. 
https://www.sphn.ch/en/organisation/elsi-advisory-group.html  
 
 Technical aspects  
www.genomeprivacy.org is a community website for sharing information about research on the 
technical protection of genome privacy and security 
 
 Practice and local governance (Geneva) 
- HUG (Geneva Hospitals) is testing the use of tablets for providing to patients access to information 
from the hospital information systems. Trust issues involved include giving access to sensitive data, 
i.e. trusting the security system with complex authentication mechanisms. 
- The Health Information Exchange project (electronic patient record), which started in 1999 was 
challenged by the distrust of the population if the data is stored on a centralized database, and if 
the project is driven by public hospitals, arguing that trust must be built with all stakeholders. In 
addition, there was an issue of inter-professional trust among practitioners. As a result, the current 
project is for a fully distributed database, and is a voluntary opt-in system both for citizens and for 
care professionals. But the driving force comes from citizens. 
- The cantonal law about the electronic patient record (2008) contains a provision that 
"Information, once anonymized, can be used to steer the health system or to support research." 
Interestingly, however, this provision was not implemented yet, because politicians are concerned 
that trust would be damaged and patients would not use the electronic patient if they know that 
their data can be used for research. 
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Box 5: UK care.data 
The UK National Health Service (NHS) launched in 2013 the care.data programme, to extract data from 
general practitioners surgeries and anonymise them for research. The programme was controversial from 
the start, notably because of lack of information to patients, and lack of clarity around options for opting out 
of the data extraction. The programme was stopped in 2014 and patients were offered the possibility to 
have their data withdrawn (opt-out). Its failure has been attributed to three main factors: ambiguity of 
derivative public good, faulty warrants of trust, and uncertainties surrounding the duties of general 
practitioners. There was a lack of faith and a lack of transparency, and many ambiguities about the whole 
programme (Carter et al., 2015; Adjekum et al., 2017). 
Participants in the workshop noted that only one in 45 individuals opted out after it was made public that 
the programme had no sufficient plan for IP/data privacy. However, the majority of UK residents continue to 
trust the NHS.  
As mentioned in section 2, people who opt out of a programme may actually not display lack of trust. They 
just display disagreement. Opt-out rates are a lousy proxy for trust. Conversely, people who opt-in in a 
programme may not trust the whole programme. 
 
 
 
 
 
References 
Adjekum A., Ienca M., and Vayena E. (2017). What Is Trust? Ethics and Risk Governance in Precision Medicine and 
Predictive Analytics. OMICS: A Journal of Integrative Biology. December 2017, 21(12): 704-710. 
https://doi.org/10.1089/omi.2017.0156 
Holm H.-J. and Nystedt H.-J. (2010). Collective trust behavior. Scand J Econ 112, 25–53. 
O'Neill O. (2002). A Question of Trust: The BBC Lectures 2002. Cambridge University Press. http://www.efc.be/human-
rights-citizenship-democracy/trust-trustworthiness-transparency/ 
Rousseau D.-M., Sitkin S.-B., Burt R.-S., and Camerer, C. (1998). Introduction to special topic forum: Not so different 
after all : A Cross-discipline view of trust. Acad Manag Rev 23, 393–404. 
Trust in Precision Medicine – background paper to the workshop 
18 
Appendix 1 - Background paper to the workshop 
Trust in Precision Medicine - A Risk Governance Perspective12 
This background paper is a working document. It sets the scene and serves as the basis for discussion for 
the expert workshop on Trust and Precision Medicine – A Risk Governance Perspective, 
23 – 24 November 2017, Campus Biotech, Geneva. 
Introduction 
This background document seeks to underlie the salience of trust for precision medicine. In the previous 
workshop on ‘Governance of impacts of precision medicine’, organised by the International Risk Governance 
Center (IRGC), trust was identified as pertinent to the success of precision medicine; hence, the premise for 
this follow-up workshop. 
Precision medicine refers to an emerging field for disease diagnostics, prevention and treatment that 
considers individual variability in genes, environment and lifestyle, with the aim of improving patients’ health 
and augmenting disease prevention (Florin & Escher, 2017). Moreover, it caters to both patients and 
healthcare professionals with respect to patient-centered care, customised patient-provider relationships 
and effective treatments (Adams & Petersen, 2016). 
To a large extent, precision medicine is driven by three main concurrent trends: (i) the increasing availability 
of heterogeneous large-scale databases from which novel patient aggregates evolve, (ii) advances in the 
characterisation of medically relevant information, and (iii) novel computational tools for data analytics 
(Adams & Petersen, 2016; Collins & Varmus, 2015). Exponential growth in data volume is a key feature of 
precision medicine. Collectively, the accumulation of these data – from genomics, proteomics, 
metabolomics and mobile health (m-health) among others – work hand in hand with improvements in basic 
research to promote the concept of precision medicine (Collins & Varmus, 
2015). 
The promises of precision medicine stem from its ability to transform healthcare approaches to research 
and delivery for the benefit of human health. National programmes in Estonia (1999) and Finland (2006) for 
instance, have demonstrated the potential benefits of precision medicine (Estonian Genome Center, 2011; 
FIMM, 2017). In 2015, US President Obama launched the Precision Medicine Initiative (PMI). A predominant 
component of the PMI is the All of US Research Program, which aims to advance precision medicine by 
combining molecular information with clinical and lifestyle data from a national research cohort of one 
million individuals (NIHa, 2017). The change in the name of the program – from PMI Cohort Program to All 
of Us Research Program – is indicative of the need for inclusivity in precision medicine (NIHb, 2017). 
There is an increasing consensus that the notion of trust is paramount to derive maximum capabilities from 
precision medicine (Hurst, 2012). A 2016 expert workshop held by IRGC identified trust as crucial to 
participant engagement since it thrives on biomedical data collection and sharing (Florin & Escher, 
2017). Similarly, Mirnezami et al. (2012) have highlighted that precision medicine “will deeply affect 
public trust and the nature of the patient-clinician relationship”, hence “it will require unprecedented 
collaboration among healthcare stakeholders.” 
Although the salience of trust in precision medicine is a recurring subject, few studies have divulged the 
subject from a conceptual standpoint. Thus, this paper seeks to underscore the salience of trust in precision 
medicine and to provide conceptual clarity by developing at least a working definition and characterisation 
of the trust dynamics. This is followed by identifying three main types of facilitators (technical, ethical and 
institutional) necessary to building and maintaining trust about precision medicine. Afterwards, we 
deliberate on the dimensions of precision medicine that have carved out trust as a pertinent tool to its 
                                                          
12 This background paper was written by Afua Adjekum, with contributions from Marcello Ienca, Marcel Bürkler, Marie-Valentine 
Florin and Effy Vayena. It reflects the view of its author and not of IRGC or any other organisations affiliated with this workshop. It 
was improved thanks to comments and suggestions from Isabella Beretta, Jacques Fellay, Samia Hurst and Adrien Lawrence. For any 
questions or comments, please contact Afua Adjekum (ETHZ,  afua.adjekum@hest.ethz.ch) and Marcel Bürkler (EPFL IRGC,  
marcel.burkler@epfl.ch). 
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success. We conclude by making some preliminary (albeit not exhaustive) recommendations on how best to 
enhance trust in precision medicine. 
What is Trust? 
Although trust is a familiar concept that cuts across a spectrum of disciplines, there is a lack of consensus on 
its definition. Besides agreeing that trust is relational (occurs between people and or entities) and context-
specific, there is continual discourse among scholars on what constitutes trust (Gilson, 2003). Trust has been 
described as a three-place relation; whereby, ‘A’ (trustor) trusts ‘B’ (trustee) to fulfil ‘C’ (task) (Baier, 1986). 
Overall, the concept of trust conveys the notion of risk and vulnerability on the part of a trustor. 
Trust is often dichotomised into affective-based trust and cognitive-based trust. The former conveys the 
notion that trust stems from conventional norms of morality which are upheld by the goodwill of others; 
whereas the latter perceives trust as a calculation or rational behaviour that involves some form of risk 
analyses (Gilson, 2003). It is important to differentiate between trust and trustworthiness even though these 
two concepts are often used interchangeably. While trust is understood as an expectation of positive motives 
(Rousseau et al., 1998), trustworthiness is perceived as a characteristic that is projected onto an individual or 
group (Holm & Nystedt, 2010). O’Neill has famously brought attention to this important distinction arguing 
further that for trust to be established, trustworthiness needs to be demonstrated. In that respect, trust is a 
response to trustworthiness, and we should aim to put “trustworthiness before trust”. (O’Neill, 2015) 
Some scholars suggest that trust is neither a choice nor a behaviour, but rather, a psychological state that is 
crucial to organisational life (Rousseau et al., 1998). Other scholars maintain that encapsulated interests, 
rational predictions of another’s behaviour as well as personality traits compel people to trust (Lang & 
Hallman, 2005). Nonetheless, reliance is at the core of trust even as it is assumed that a pure trust 
relationship exists when emotions such as gratitude, betrayal and resentment – ‘reactive attitudes’ – are 
expressed if expectations go unmet (Holton, 1994). 
Trust is also at the helm of social cohesion even as it projects its existence – or lack thereof, – on all aspects 
of social interactions. Social norms are said to shape individuals’ beliefs and inherent in such beliefs is trust, 
which in turn cultivates cooperation and vice versa (Gilson, 2003). Within a trustworthy society, individuals 
balance into equilibrium both interpersonal trust (trust in individuals) and institutional trust (trust in the 
social system) (Gidman et al., 2012). However, although many scholars agree that these forms of trust rely 
on each other, they are yet to fully understand their underlying relationship (Gidman et al., 2012; Rousseau 
et al., 1998). 
Societies with optimum levels of trust witness lower transaction costs, conflict aversion within organisations 
in addition to optimum cooperative behaviour (Rousseau et al., 1998). Within the health system, trust 
facilitates patient satisfaction, adherence to treatments, health provider continuity, patient disclosures and 
encourages access to health facilities (Gidman et al., 2012). It is important to note that trust cannot just be 
produced or generated, but must consistently be accumulated and reinforced by performance or experience 
(IRGC, 2005). Furthermore, the presence of conflicts of interests raises specific challenges regarding the 
maintenance of both trust in and trustworthiness of physicians, which requires special attention (Hurst, 
2017). 
In instances where there is low generalised trust (individuals’ expectations of the trustworthiness of others) 
(OECD, 2017), mistrust and distrust are likely to thrive. Mistrust denotes ‘unhealthy cynicism’ resulting from 
a prior breach of trust while distrust, comprises of ‘healthy scepticism’ (Abelson et al., 2009). From this 
description, trust can be envisioned as a spectrum containing positive and negative peripheries: on the 
positive end sits ‘trust’, with ‘mistrust’ on the negative end. As McAllister argues “the amount of knowledge 
necessary for trust resides somewhere between total knowledge and total ignorance [...] Given total 
knowledge, there is no need to trust, and given total ignorance, there is no basis upon which to rationally 
trust”. McAllister (Mcallister 1995, pp. 26). 
As much as precision medicine relies on disease patterns to recognise trends, researchers relish voluntary 
data contributed by healthy individuals. Integral to this paradigm is the belief or expectation that personal 
data will not be used against the owner of the data and there will be a derivative public good (Bourzac, 
2016). A study conducted by researchers at the US National Institute of Health confirms this as individuals’ 
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willingness to participate in the All of Us program involves some risk and benefit analysis (Kaufman et al., 
2016). 
Based on these evaluations, a working definition of trust in precision medicine could be the willingness of a 
trustor to accept the potential risks involved in the use of their sensitive health-related data resulting from 
both optimism about the trustees’ goodwill, interest in the public good, and capacity to limit these risks. 
While a trustor can be both an individual and a multi-individual entity (e.g. a corporation, research group 
or other organisation), we are particularly concerned in this paper with the issue of trust from the 
perspective of the single individual towards the data initiatives for precision medicine.  
In fact, we consider the individual citizen to be the fundamental and atomic unit of trust. The reason for that 
stems from the fact that the individual citizen or natural person is the social actor to which fundamental 
human rights can be granted. Although 
beyond the scope of this paper, another reason may be 
due to trust acting as a psychological state influenced by a 
plethora of factors. 
It is also important to point out that trust dynamics are 
often multi-layered and might follow chain reaction 
patterns. In fact, when sharing data with a certain trustee 
Y, a trustor X should not simply trust Y, but also all actors 
that Y might further share X’s data with. The longer the 
chain of trust, the harder it is for the individual to predict 
the risks and benefits of her voluntary data contribution as 
well as to assess the trustworthiness of all trustees 
involved. This problem is exacerbated by the fact that, in 
many circumstances, the individual citizen might have only 
partial (if any) knowledge about actors beyond the first 
trustee. 
Figure 1: The complex data sharing relationship between a trustor and relevant trustees (either individuals or 
institutions). The arrows indicate the various trust relationships are occurring at different phases of the data-sharing 
process. The fading represents diminishing trustors' knowledge about data-sharing mechanisms and actors. 
Some Facilitators for Sustaining Trust 
The drivers for building trust in precision medicine can be categorised into three: 1) technological 
innovation, 2) ethical and sociocultural values and 3) institutional practices & governance measures. In this 
section, we discuss these three drivers. 
1) Technological innovation is a viable means of facilitating accountability relating to data sharing, quality 
and integrity. 
For example, the White House published a “Data Security Policy Principles and Framework (Security 
Framework)” that healthcare organisations are advised to follow to secure data in the All of Us program, 
recommending to be “careful not to poison the well-being of patient trust”. A typical example is blockchain 
technology, which refers to a digital ledger made up of linked peer-to-peer transaction blocks on which 
unalterable records are shared. The features of the blockchain make it potentially well-suited to address the 
disjointed nature of health-related records by eliminating the need to rely on third parties for their security 
(Krawiec et al., 2016). Consequently, the blockchain aims to improve the protection of privacy, security and 
to enable interoperability in health and medical data transactions (IRGC, 2017a). 
Differential privacy and homomorphic encryption are technological solutions that have been proposed to 
minimise the risks associated with the use of sensitive data13. These approaches aim to uphold the analysis 
of databases containing confidential information by, among others, minimising the risks associated with the 
re-identification of anonymised data (Dwork & Roth, 2014). In ensuring a high standard of data 
                                                          
13 See for example www.genomeprivacy.org 
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anonymisation –  by shrinking the risks associated with being re-identified with publicly available data for 
instance – individuals are more likely to participate in precision medicine initiatives. 
It is crucial to recognise that technology alone cannot ensure that citizens and other stakeholders place their 
full trust in the advances that precision medicine has to offer. It can help build and sustain trust by reassuring 
participants of the privacy and security of their sensitive data as well as increasing the capacity to protect 
against impending risks. However, technology as a tool to help build and sustain trust in precision medicine 
would only attain optimum results if it accompanies sound medical analysis coupled with meaningful and 
equitable relationships with citizens. 
2) Acknowledging the importance of ethical and socio-cultural values as facilitators to trust in 
precision medicine stems from experiences with trust in similar conditions.  
The relevance of transparency and public trust in novel biomedical research has been echoed ever since 
major strides were accomplished in recombinant DNA and beyond (Baltimore et al., 2015). Concerning 
precision medicine, it is essential to prioritise transparency – built on public engagement – that ranges from 
healthcare delivery, research and institutional management practices. 
Preferred forms of consent, data sharing in addition to the motivations for participation must constantly be 
assessed to alleviate participant concerns (Kaufman et al., 2016). In prioritising the participant (trustor), the 
researcher or health personnel (trustee) is better able to relay their proficiency to undertake the tasks 
assigned them and likely reinforce their goodwill. This matters as, for example, the information sheets and 
consent forms that are used during research projects have been shown to merely serve as ‘symbolic tokens’. 
Instead, participants’ ‘faith’ in the objective of the project and assurance of minimal risks that is what 
motivates them to participate (Carter et al. 2015). 
Public engagement strategies based on communication are another tool that is widely used to assess ethical 
and sociocultural values. Communication in public engagement strategies is understood as a two-way 
dialogue between relevant stakeholders and the public. Good practices in risk communication help 
stakeholders make informed choices about matters of concern to them and hence create mutual trust (IRGC, 
2005). The absence of dialogue-based communication regarding the roles and expectations of both a trustor 
and trustee results in misplaced trust. 
Stakeholder engagement on a broad scale supports better decision-making (IRGC, 2017b). Involving all the 
entities to whom precision medicine matters will enable the identification and prioritisation of the 
motivations behind individuals’ values and interests. In a survey conducted by Kaufman et al. (2016) thirty 
percent of survey participants changed their willingness to participate after being informed of the potential 
risks and benefits of the PMI cohort study. This suggests the importance of consistent stakeholder 
engagement prior and during precision medicine initiatives. 
3) Institutional practices and governance are involved in building social cohesion, making them critical 
trust facilitators.  
Gilson (2003) maintains that institutions (both public institutions and other social organisations including 
private ones) bolster the social order by ensuring interpersonal trust, which in turn strengthens generalised 
trust. Hence, management practices and decisions do not only matter to those said institutions but to 
society as a whole. Equity, fairness and a general sense of prioritising the public good at the institutional 
or governance levels all stand to foster trust in precision medicine and society as a whole. 
Public institutions that aim to foster trust must communicate about their competence and values as they 
are perceived by the public. Competence is the capacity to undertake an intended task, while values foretell 
the intentions and ethics of the said institution (OECD, 2017). However, inasmuch as competence and values 
matter, it is crucial to bear in mind that individuals’ overall trust judgements regarding an organisation are 
equally influenced by transparency and openness, public interest (organisational aim to tackle bias) and 
honesty (truthful about risk) (Lang & Hallman, 2005). 
Governance models include a variety of options such as incentives, frameworks, initiatives, guidelines, or 
public regulation (IRGC, 2012). Institutions that implement effective governance approaches are better 
equipped to achieve a common ground for measurable, transparent and comparable quality standards. In 
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the case of precision medicine, the standardisation of precision medicine initiatives can contribute to 
building public trust. An example of governance relevant for precision medicine is the Committee of 
Ministers of the Council of Europe Recommendation CM/Rec (2016)6. The committee emphasises the 
importance of building trust. It contains specific guidelines for research on biological materials of human 
origin. It recommends that EU governments adapt their laws and practices to ensure the implementation of 
the guidelines and promote the establishment of codes of conducts to ensure compliance with the 
guidelines. The Committee aims to safeguard the fundamental rights of individuals from whom biological 
materials are obtained, stored and used (Council of Europe 2016). 
Generic guidelines for medical research also prove useful to standardising institutional practices. In 
Switzerland, swissethics, a joint working group of Ethics Committees addresses ethical issues relating to 
research on humans, educates and trains members, as well as standardises and coordinates their actions 
(swissethics, 2017). 
Schlesinger and Gray (2016) argue that trustworthiness is never guaranteed in healthcare due to the 
challenges involved with measuring trust within this setting, combined with the ubiquity of provider 
discretion. Yet, studies show that experts and organisations can favourably impact public perception, which 
in turn helps to advance efforts to build and maintain overall trust within society. As a result, efforts to build 
and sustain trust in precision medicine must recognise and acknowledge this paradigm moving forward. 
How to Achieve Trust in Precision Medicine? 
Precision medicine depends on the aggregation of a broad quantity and variety of individuals’ private data. 
Typical health data sources such as medical records, results of laboratory tests, genomics, immunisation 
records, are supplemented with, among others, data from self-tracking devices, loyalty cards, store 
transactions, wellness and social media (Vayena et al., 2017). For these heterogeneous data to be available 
(hence, for such data aggregation to be possible), researchers and clinicians need to rely on voluntary data 
contributions from individuals. Since familiarity is vital to building and maintaining trust, it will take some 
time to ensure public acquaintance with these novel health data sources and stakeholders. In addition, 
increasing breadth and variety of data sources will increasingly require collaborative efforts between 
several disciplines as well as novel stakeholders. 
Furthermore, precision medicine relies heavily on sensitive personal data that may be made available to new 
and previously unfamiliar actors in healthcare. Reports indicate that health data is currently more valuable 
than credit card information, and cyber incidents at health organisations have increased from 20% in 2009 to 
40% in 2013 (Reuters, 2014). This calls for an increased need to ensure optimum health data privacy and 
security. Strengthening regulation concerning negligence with health data might be necessary to combat 
health data breaches. However, increasing regulations often tends to adversely affect institutional trust 
(Calnan & Rowe, 2007). 
It is vital to consider these elements in the future to avoid repeating past and even novel mistakes. In 
2012, under the Health and Social Care Act, the NHS proposed the care.data initiative. Despite meeting 
all of the legal prerequisites required to exploit medical records for research, care.data floundered (Sterckx 
& Cockbain, 2014; Carter et al., 2015). Its failure has been attributed to three main factors: (1) ambiguity of 
derivative public good, (2) faulty warrants of trust, and (3) uncertainties surrounding the duties of general 
practitioners. Indeed, it was not inadequate publicity that derailed care.data, but rather, an absence of faith 
and a lack of transparency compounded by ambivalence about the risks involved (Carter et al. 2015, pp. 3)14. 
More recently the NHS England had another controversial collaboration with Google’s DeepMind. In this 
case, DeepMind received access to millions of identifiable patient data to develop applications that would 
support patients with kidney disease. An investigation of the data sharing agreement between DeepMind 
and the NHS by the UK’s National Data Guardian concluded that this arrangement took place on an 
inappropriate legal basis (Revell, 2017; Powles & Hudson, 2017). (See Box A below)  
                                                          
14 care.data has been relaunched in the form of NHS Digital: https://digital.nhs.uk 
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Box A: The crucial role of engaging with stakeholders through transparency and communication – 
The NHS care.data initiative and DeepMind in the UK 
NHS 
In 2013, National Health Service (NHS) England launched care.data, a programme aimed to combine health and 
social care data, including patient records stored on machines of general practitioners or from hospitals. Its main 
goal was for researchers to use the anonymised patient data to assess the performance of NHS services and to 
develop new treatments. However, the initiative faced constant criticism over the sharing of medical information 
with commercial third parties without explicit patient consent as well as over data security and confidentiality 
concerns. When it was disbanded, over one million people had already opted out of the programme. This lack of 
trust and ultimately the failure of the programme were mainly blamed on unclear mechanisms of consent and 
criteria for accessing the collected health data, and the fact that communication with the public was not 
prioritised (Presser, 2015; Temperton, 2016). 
DeepMind 
In an effort to develop ‘Patient Safety Alerts for Acute Kidney Injury (AKI)’ clinicians from the Royal Free London NHS 
Foundation Trust solicited the help of Google DeepMind Technologies Limited (an artificial intelligence and machine 
learning company) in July 2015. By November 2015, sensitive and identifiable patient data had been transferred 
from the Royal Free to third-party data processing entities contracted by Google. DeepMind publicised this 
relationship in February 2016 claiming to act merely as a channel through which real-time analysis and alert 
systems for AKI is provided through the app ‘Streams’. After an independent investigation by the New Scientist, 
both parties were compelled to elaborate on the uses of the data. However, to date, little is known about the overall 
uses of the data, the reasons why more data than required was transferred, the reasons for bypassing relevant data 
governing entities nor the failure to obtain patients’ consent. Consequently, tremendous doubts have been raised 
about the underlying motive for the programme (Powles & Hodson, 2017). 
The two controversial cases above highlight problems that can easily emerge in the sensitive space of 
patient data. They also illustrate some specific aspects that can facilitate our consideration of how best to 
promote trust in the data-rich environment of precision medicine. Below is a preliminary list of 
suggestions: 
First, we identify a need for the widespread implementation of technical facilitators of trust in precision 
medicine initiatives. These include, but are not restricted to, blockchain, differential privacy or 
homomorphic encryption technology. On the long term, the successful implementation of security & 
privacy-enhancing techniques might enhance existing security protocols and models regarding both 
format and structure and “add additional layers of security and trust” (Versel, 2017). In fact, these 
technologies potentially allow to disintermediate data from hosts, increase transparency and process 
integrity, increase the ability to withstand data leakage and malicious attacks, and ultimately empower 
trustors. Therefore, this is likely to have a positive effect not only on the management of healthcare data 
but also on their large-scale collection as well as on the social dissemination of scientific findings. 
Concurrently, this technical transition should be coordinated with the responsible promotion of ethical 
and socio-cultural facilitators. Ethical values such as privacy, transparency and fairness are likely to be 
co-determinants of trust at both the individual and collective levels. They should be prioritised to 
maximise the benefits of precision medicine in an ethically and sustainable manner. Therefore, public 
engagement and awareness-raising activities should be incentivised to enable competent decision making 
within the precision medicine ecosystem, especially from the perspective of the trustor-trustee 
relationship. As the failure of the care.data initiative indicates, stakeholder engagement should be 
sustained through unambiguous anticipation of derivative public good, reliable warrants of trust, and a 
clear specification of the duties of health professionals. 
Finally, calibrated institutional interventions and governance solutions should be advanced to enhance 
trust in precision medicine and orient research for the public good. A good example in this direction is 
represented by Switzerland, where, in recent years, several institutional initiatives have been proposed. 
The Swiss Personalized Health Network (SPHN) prioritises respect for persons, privacy, data fairness and 
accountability. It has put forward the ‘Ethical Framework for Responsible Data Processing in the Swiss 
Personalized Health Network’ (SPHN ELSI Advisory Group, 2017). Ideally, these networks of researchers 
should be established not only at the national level but also internationally. An initiative taking this 
international approach (albeit focusing on genomics) is the Global Alliance for Genomics and Health. 
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Platforms may also facilitate dialogue and information sharing not only between researchers but also 
between the PM research and other societal actors. Finally, to promote and sustain trust in PM research, 
institutional review board (IRBs) and other deliberative assemblies should clearly define effective and 
reliable ethical review processes for PM research. Table 1 below summarises our analysis of trust 
facilitators and the subsequent points of consideration. 
Table 1: Overview of Trust Facilitators in Precision Medicine 
Type of Trust 
Facilitator 
Points of 
Consideration 
Normative Suggestions Examples 
Technical - Value of sensitive data 
- Susceptibility to 
data breaches 
- Disintermediating data from hosts 
- Increasing transparency & 
process integrity 
- Reducing vulnerability to data 
leakage and malicious attacks 
- Differential privacy 
- Blockchain 
- Encryption 
Ethical/Socio
- cultural 
Unfamiliarity of the 
public with novel 
healthcare actors 
- Prioritising privacy, transparency and 
fairness 
- Promoting public engagement & 
awareness 
- Unambiguously anticipating 
public good 
- Identifying reliable warrants of trust 
- Privacy protection 
- Accountability 
mechanisms 
- Transparency of 
process 
- Fair benefit sharing 
plans 
- Public engagement 
Institutional - Data misuse 
- Benefit sharing 
- Establishing international 
networks of researchers 
- Creating trustworthy platforms for 
exchange between 
- Defining a clearer ethical process for 
precision medicine research 
- Standardised 
guidelines 
- Ethical review 
recommendations 
Conclusion 
Trust is essential in precision medicine. However, the characterisation of trust dynamics in this rapidly 
evolving field of medicine is often affected by uncertainty and conceptual variability. In this paper, we provide 
a definition of trust and a detailed characterisation of trustor-trustee dynamics in precision medicine. We 
highlight that trust is necessary for facilitating participants’ involvement in precision medicine initiatives. 
It is a catalyser for socially responsible scientific advancement and practical implementation in this field. 
Technical solutions, ethical and sociocultural values, as well as effective governance measures, are all 
identified as facilitators of trust in precision medicine. Based on this analysis and learning from previous 
precision medicine initiatives, we see a need to formulate a minimal set of recommendations aimed at 
mitigating the risks associated with the sharing of sensitive data, increasing transparency, empowering 
trustors and augmenting public trust in precision medicine. 
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Appendix 2 - Questions discussed during the workshop 
The programme of the workshop was organised to discuss the following questions: 
 What is 'trust' and ‘trustworthiness’ in the era of big data and precision medicine? What are the risks if trust is 
lacking or incomplete? How can we achieve trustworthiness? Can trust be measured? Can it be mandated? 
 Could novel technologies help build trust? 
 Role and responsibility of the medical sector in contributing to building trustworthy relationships with patients and 
citizens; 
 Role and responsibility of the private sector in contributing to building trust 
Breakout groups were also organised to discuss: 
Group 1: Data collection, access and use 
 Is there sufficient trust in or understanding of the idea of using personal genetic, medical and health data to drive better 
care through precision medicine? 
 The personal data issue is critical for regulators. Does the behaviour of patients and citizens indicate that it is also critical 
for them that their personal data are strictly protected? 
Group 2: Voluntarist campaigns vs. Proof of concept 
 Can small-scale “proof of concept” be more efficient than discursive claims and voluntarist campaigns for trustworthy 
precision medicine? 
 What are the good practices for a strategy of incremental steps? 
Group 3: Promises and delivery 
 Is there over-promising and under-delivery by important actors of precision medicine, such as industry, clinical research 
or translational research?  
 If yes, does this affect trust in precision medicine by medical doctors, patients and citizens?  
Group 4: Transparency  
 To what extent can transparency provide evidence of trustworthiness? (potentials and limitations of transparency to 
help build trust in precision medicine, for example through informed consent)  
 Is transparency in cost/pricing and payment/reimbursement important for trustworthy relations with industry, 
regulators and payers? 
Group 5: Communication 
 Do the messages conveyed within and outside medical practices follow the best evidence and good practices in risk 
communication? 
 How to use communication to improve trustworthiness? 
Group 6: Industry  
 What can industry do to be perceived as a competent, reliable, accountable and honest partner in the development of 
precision medicine? 
 What are the obstacles to industry being perceived as a trustworthy partner, and how to overcome them? 
Group 7: Patients and citizens 
 How can patients and citizens be confident that the science and technology of precision medicine, and medical 
practitioners will help provide the best treatment for them?  
 How can they be confident that their data will not be used in a way that could cause prejudice to them? Give 
patients/citizens full control over the use of their data? 
Group 8: Medical 
 How can medical professionals build trustworthy relations with their patients and, in general, participate in building 
trust in precision medicine? 
 What are the perceived obstacles? 
Group 9: Co-developing a narrative for trust in precision medicine 
How to organise the collaborative development of a narrative that serves to create the context in which various 
stakeholders will develop trustworthy relations?   
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Nicholas, Nesta/(London's Global University) UCL; Kenneth Oye, Massachusetts Institute of Technology 
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Ronchi, Organisation for Economic Co-operation and Development (OECD); Mark Rubin, Department for 
BioMedical Research, University of Bern; Eric Salobir, OPTIC; Sigrid Sterckx, Ghent University; Effy Vayena, 
ETH Zürich; Daniel Widrig, Bristol-Myers Squibb; David Winickoff, Organisation for Economic Co-operation 
and Development (OECD). 
This workshop summary has been reviewed in draft form by the participants in the workshop, but they 
have not seen the final version before its release. Responsibility for the final content rests entirely with the 
rapporteur, Marie-Valentine Florin, with contributions and editing by Kujtesë Bejtullahu-Michalopoulos. 
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About IRGC 
The International Risk Governance Center organises IRGC activities, emphasising the role of risk 
governance for issues marked by complexity, uncertainty and ambiguity, and focusing on the creation of 
appropriate policy and regulatory environments for new technologies where risk issues may be important. 
More information on irgc.epfl.ch 
The International Risk Governance Council (IRGC) based at EPFL, Lausanne, Switzerland, is an independent 
non-profit foundation whose purpose it is to help improve the understanding and governance of systemic 
risks that have impacts on human health and safety, the environment, the economy and society at large. 
IRGC’s mission includes developing risk governance concepts and providing risk governance policy advice to 
decision-makers in the private and public sectors on key emerging or neglected issues. IRGC was 
established in 2003 at the initiative of the Swiss government and works with partners in Asia, the US and 
Europe. More information on irgc.org. 
IRGC’s work on precision medicine include  
 2015: Collection and use of genetic information (with Tsinghua University, Beijing - 
https://www.irgc.org/event/collection-and-use-of-human-genetic-information-for-precision-medicine/) 
 2016: Adaptive risk governance  (with UCL, London, https://www.irgc.org/event/planning-adaptive-risk-
regulation/) 
 2016: Governance of impacts of precision medicine 
(https://irgc.epfl.ch/cms/site/irgc/lang/en/events/workshops/precismed-Sept2016); Publication of a 
‘roadmap for the development of precision medicine’ 
(https://irgc.epfl.ch/cms/site/irgc/lang/en/projects/precision-medicine/roadmap) recommending 
inclusive and incremental strategies 
 2017: ‘Trust and Precision Medicine’ (workshop about the importance and components of trust and 
trustworthiness in the relationship between actors - https://irgc.epfl.ch/cms/lang/en/pid/148683) 
 2018: Expert meeting on ‘The Economics of Precision Medicine’ (to discuss issues of cost-effectiveness 
and innovation in payment systems) 
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